Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 3/20 | 0.53 |
| ▸ | CASP2 | P42575 | 1/20 | 0.47 |
| ▸ | NAAA | Q02083 | 1/20 | 0.45 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | GLP1R | P43220 | 5/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.41 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13640257 | 0.97 | FAAH (0.50) | FAAHCASP2NAAACES2GLP1R | |
| SCHEMBL13640268 | 0.94 | GLP1R (0.48) | FAAHCASP2NAAACES2GLP1R | |
| SCHEMBL13640271 | 0.94 | GLP1R (0.48) | FAAHCASP2NAAACES2GLP1R | |
| SCHEMBL13640252 | 0.89 | FAAH (0.47) | FAAHCASP2GLP1RMEN1KMT2A | |
| SCHEMBL17167854 | 0.88 | FAAH (0.46) | FAAHCASP2NAAAGLP1RMEN1 | |
| SCHEMBL12743582 | 0.87 | FAAH (0.49) | FAAHCASP2NAAAGLP1RMEN1 | |
| SCHEMBL26412119 | 0.87 | FAAH (0.57) | FAAHCASP2NAAACES2GLP1R | |
| SCHEMBL13880451 | 0.87 | FAAH (0.51) | FAAHCASP2NAAAMEN1KMT2A | |
| SCHEMBL13640260 | 0.85 | MEN1 (0.49) | FAAHCASP2NAAAGLP1RMEN1 | |
| SCHEMBL13640275 | 0.85 | GLP1R (0.46) | FAAHGLP1REPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9012398-B2 | Acylated exendin-4 compounds | NOVO NORDISK A/S (DK) | 2015-04-21 | — | — | US | disclosed |
| US-20120283170-A1 | Acylated Exendin-4 Compounds | NOVO NORDISK A/S (DK) | 2012-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283170-A1 | Acylated Exendin-4 Compounds | GLP1R, VIP, IAPP | FAAH 163/4885CASP2 2065/4885NAAA 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.